Alembic Pharmaceuticals received 8 USFDA approvals in Q3FY24
The company has received five final approvals
The company has received five final approvals
AMP-6 & AMP-8 are special purpose entities formed for purpose of setting up captive solar power projects in Karnataka
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
According to Sun Pharma, the purpose of the strategic investment is to obtain access to the technology for certain compounds and territories while also fostering the development of novel pharmaceutical delivery systems.
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
The product is expected to be launched in December 2023
Syngene has completed a payment of Rs. 158.2 crores on December 22, 2023 in addition to the initial payment of Rs. 395 crores made on December 1, 2023
Trinity has availed credit facility from Investec for Business for their working capital requirements of Rs. 31.5 crore
JB Chemicals will pay Rs 125 crore to Novartis to license the same drug portfolio for the Indian market
Subscribe To Our Newsletter & Stay Updated